News Sentiment

MPLT sentiment intelligence

MapLight Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 75 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 39.32 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 67

directly relevant articles

Source quality 7

high-authority source matches

Trend context Trend active

+6.0% over one week, +41.7% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Why Did Vir Biotechnology Stock Surge 60% After-Hours Today?

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction 6.0% Price confirming higher
Trend fit Trend active 41.7% over four weeks
Fair value 75.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 20
Neutral 49
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 67
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
TradingView 8
MarketBeat 4
MT Newswires 3
Seeking Alpha 3
Investing.com 3
simplywall.st 3
Investing.com Canada 2

Event Lens

What the news is about

Classified themes
Market update 37
Earnings 24
Analyst action 11
Deals and strategy 1
Balance sheet 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 75
Investing.com Nigeria Direct company coverage

Form 144 MapLight Therapeutics For: 15 July By Investing.com

This article reports on a Form 144 filing for MapLight Therapeutics on July 15. It is a very brief announcement, primarily consisting of the headline repeated in the body. The article originates from Investing.com and was published on July 15, 2026.

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 21:14
Source
Investing.com Nigeria
MarketBeat Direct company coverage

Maplight Therapeutics (NASDAQ:MPLT) Sees Large Volume Increase on Analyst Upgrade

Maplight Therapeutics (NASDAQ:MPLT) experienced a significant increase in trading volume after Needham & Company raised its price target and reaffirmed a buy rating. Despite positive analyst sentiment, with a consensus "Buy" rating and an average price target of $39.10, the compa

Tone
Neutral 50/100
Event
Analyst action
Published
10 Jul 2026 15:39
Source
MarketBeat
MarketBeat Direct company coverage

Needham & Company LLC Raises Maplight Therapeutics (NASDAQ:MPLT) Price Target to $45.00

Needham & Company LLC has increased its price target for Maplight Therapeutics (NASDAQ:MPLT) from $42.00 to $45.00, maintaining a "buy" rating and suggesting a 13.07% potential upside. This comes amidst a mixed analyst sentiment, with several firms reiterating "buy" ratings while

Tone
Positive 63/100
Event
Analyst action
Published
10 Jul 2026 12:39
Source
MarketBeat
Investing.com Canada Direct company coverage

Needham raises MapLight Therapeutics stock price target on trial data By Investing.com

Needham has increased its price target for MapLight Therapeutics (NASDAQ:MPLT) to $45 from $42, maintaining a Buy rating. This adjustment comes as the firm raised the probability of success for MPLT's lead schizophrenia candidate, ML-007-MC, from 55% to 60%, with promising early

Tone
Positive 67/100
Event
Analyst action
Published
10 Jul 2026 11:40
Source
Investing.com Canada
Finviz Direct company coverage

MPLT - MapLight Therapeutics Inc Options

This page provides a detailed financial overview of MapLight Therapeutics Inc (MPLT), including its last closing price, key financial metrics such as market cap, income, and sales, and various performance indicators. It also presents information on ownership, profitability, and s

Tone
Neutral 50/100
Event
Market update
Published
05 Jul 2026 05:41
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBIT forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT

This article focuses on the enterprise value to EBIT forward for MapLight Therapeutics, Inc. (NASDAQ: MPLT). It appears to be a financial data page from TradingView, providing financial oversight for the company. The content primarily lists navigation links and disclaimers rather

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 08:11
Source
TradingView
Market source Direct company coverage

Is MapLight Therapeutics, Inc. (MPLT) Stock a Biotech Opportunity Ahead of the ZEPHYR Trial Readout?

MapLight Therapeutics, Inc. (MPLT) is considered a top biotech stock by analysts, with Raymond James initiating a "Strong Buy" rating and a $46 price target. The company has upcoming catalysts including the Phase 2 ZEPHYR trial readout for ML-007C-MA by mid-August and an Alzheime

Tone
Positive 63/100
Event
Analyst action
Published
30 Jun 2026 15:38
Source
Market source
TradingView Direct company coverage

Number of shareholders of MapLight Therapeutics, Inc. – NASDAQ:MPLT

This article provides details on how to find the number of shareholders for MapLight Therapeutics, Inc. (NASDAQ: MPLT) on TradingView. It directs users to the financial section of the company's profile where this information would typically be located, alongside other financial d

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 04:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT

This article provides financial information for MapLight Therapeutics, Inc. (NASDAQ: MPLT), specifically focusing on its forward price-to-book ratio. The content states that the market for MPLT is currently closed with no trades. It appears to be a stub or data-oriented page from

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 12:40
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT

This article focuses on the "Price to earnings forward" metric for MapLight Therapeutics, Inc. (NASDAQ: MPLT). It is presented on a financial data platform page, likely from TradingView, indicating a focus on financial analysis for investors interested in the company's valuation.

Tone
Neutral 50/100
Event
Earnings
Published
28 Jun 2026 21:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of MapLight Therapeutics, Inc. – NASDAQ:MPLT

This article provides a brief mention of the "Price to sales forward" metric for MapLight Therapeutics, Inc. (NASDAQ: MPLT). It appears to be a financial data point available on TradingView, indicating a period value and changes in percentage.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 09:10
Source
TradingView
TradingView Direct company coverage

MPLT Forecast — Price Target — Prediction for 2027

This article provides an overview of MapLight Therapeutics, Inc. (MPLT) stock, including its current price, analyst forecasts, historical performance, and financial data. It highlights that analysts predict a max estimate of $48.00 and a min estimate of $30.00 for MPLT's future p

Tone
Positive 70/100
Event
Analyst action
Published
26 Jun 2026 09:09
Source
TradingView
MarketBeat Direct company coverage

Maplight Therapeutics (MPLT) Short Interest & Short Float | Updated Jun 2026

Maplight Therapeutics (MPLT) reported a short interest of 1.90 million shares as of June 15, 2026, marking a 21.59% increase from the previous report and representing 4.63% of its public float. The short interest ratio (days to cover) stands at 6.5, indicating it would take this

Tone
Negative 32/100
Event
Market update
Published
26 Jun 2026 09:09
Source
MarketBeat
Investing.com South Africa Direct company coverage

Form 4 MapLight Therapeutics Inc For: 25 June By Investing.com

This article reports on the Form 4 filing for MapLight Therapeutics Inc. on June 25, indicating that the information is relevant for investors following insider transactions. It directly states the filing information and includes the company's stock performance details.

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 06:09
Source
Investing.com South Africa
TradingView Direct company coverage

MapLight Therapeutics, Inc. Actuals & Estimates (NASDAQ:MPLT)

This article provides key financial data and analyst estimates for MapLight Therapeutics, Inc. (NASDAQ: MPLT), including current stock price, market capitalization, historical performance, and future forecasts. It details the company's past earnings and revenue, upcoming earnings

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 03:09
Source
TradingView
Seeking Alpha Direct company coverage

Tonix, MapLight are new Strong Buys at Raymond James on upcoming catalysts

Raymond James has initiated coverage on Tonix Pharmaceuticals (TNXP) and MapLight Therapeutics (MPLT) with Strong Buy ratings, setting price targets of $26 and $46 per share, respectively. The analyst, Tiago Fauth, cited upcoming catalysts as the basis for these positive recommen

Tone
Positive 91/100
Event
Analyst action
Published
25 Jun 2026 10:54
Source
Seeking Alpha
Moomoo Direct company coverage

MapLight Therapeutics Appointed Martin Babler, Troy Cox to Bd >MPLT

MapLight Therapeutics has announced the appointment of Martin Babler and Troy Cox to its Board of Directors. This move aims to strengthen the company's leadership as it continues to advance its therapeutic pipeline.

Tone
Positive 67/100
Event
Market update
Published
24 Jun 2026 13:10
Source
Moomoo
Investing.com Direct company coverage

MapLight Therapeutics appoints two directors to board

MapLight Therapeutics (NASDAQ:MPLT) has appointed Martin Babler and Troy Cox to its Board of Directors following their election at the company’s Annual Meeting of Stockholders on June 23, 2026. Babler joins the Audit Committee, while Cox will chair the Nominating and Corporate Go

Tone
Positive 66/100
Event
Market update
Published
24 Jun 2026 12:11
Source
Investing.com
The Manila Times Direct company coverage

MapLight Therapeutics Announces Changes to Board of Directors

MapLight Therapeutics has appointed Martin Babler and Troy Cox to its Board of Directors following their election at the Company’s Annual Meeting of Stockholders on June 23, 2026. They succeed Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D. Mr. Babler will join the Audit Comm

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 11:11
Source
The Manila Times
Sahm Direct company coverage

MapLight Therapeutics Autism Drug Shows Mixed Potential In Adolescents

MapLight Therapeutics Inc. (NASDAQ: MPLT) announced mixed results from its Phase 2 IRIS study of ML-004 for autism spectrum disorder, missing the primary endpoint for social communication but showing significant improvement in irritability for a subgroup of adolescents. The drug

Tone
Positive 59/100
Event
Earnings
Published
23 Jun 2026 14:10
Source
Sahm
GuruFocus Direct company coverage

MPLT Maintained by Needham -- Price Target Raised to $42.00

Needham analyst Ami Fadia has maintained a "Buy" rating for MapLight Therapeutics (MPLT) and raised the price target from $37.00 to $42.00, reflecting a positive outlook on the company's potential in treating central nervous system disorders. Despite this optimism, the company's

Tone
Positive 62/100
Event
Analyst action
Published
22 Jun 2026 18:39
Source
GuruFocus
Investing.com Direct company coverage

MapLight’s autism drug trial misses primary endpoint

MapLight Therapeutics Inc. (NASDAQ:MPLT) announced that its Phase 2 IRIS trial for ML-004 in autism spectrum disorder failed to achieve its primary endpoint, which was the improvement in social communication deficits. Despite this setback, the company's shares have shown resilien

Tone
Negative 37/100
Event
Market update
Published
22 Jun 2026 13:09
Source
Investing.com